%0 Journal Article
%A Aziz, N. Ahmad
%A Claassen, Daniel
%A Petersén, Åsa
%A Weydt, Patrick
%A Network, European Huntington's Disease
%A Group, Huntington Study
%T β-Blocker effects in huntington's disease: A caution on clinical interpretation.
%J Journal of Huntington's disease
%V Advance online publication
%@ 1879-6397
%C Amsterdam
%I IOS Press
%M DZNE-2025-01422
%P -
%D 2025
%X A recent retrospective analysis of Enroll HD data suggesting β-blockers slow Huntington's disease progression has triggered patient demand but requires caution. The findings rely solely on small observational subsets and are vulnerable to bias and confounding. A prior Mendelian-randomization study found no causal link between β-blockers and HD onset; instead, genetically higher blood pressure was associated with later onset, raising concern that β-blockers' BP-lowering effects could be harmful. HD patients also have lower hypertension rates, and β-blockers carry risks such as depression and bradycardia. Given their heterogeneous mechanisms, rigorous experimental and clinical trials are needed before any clinical recommendations.
%K bioethics (Other)
%K biostatistics (Other)
%K clinical care (Other)
%K clinical trials (Other)
%K ethics (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41395805
%R 10.1177/18796397251401745
%U https://pub.dzne.de/record/282970